Report : Europe Microbiome Therapeutics Market Forecast to 2030 - Regional Analysis - by Type (Therapeutics and Procedure), Application (Metabolic Disorder and Obesity, C. Difficile Infection, Inflammatory Bowel Disease, and Others), and End User (Hospitals and Clinics, Ambulatory Surgical Centers, Homecare, and Others)
At 10.2% CAGR, Europe Microbiome Therapeutics Market is Speculated to be Worth US$ 212.52 Million by 2030, Says Business Market Insights
According to Business Market Insights' research, the Europe microbiome therapeutics market was valued at US$ 97.74 million in 2022 and is expected to reach US$ 212.52 million by 2030, registering a CAGR of 10.2% from 2022 to 2030. Technological advancement in human microbiome therapeutics and inflow of funds to ameliorate microbiome discovery pipeline are among the critical factors attributed to the Europe microbiome therapeutics market expansion.
Technological advancements have facilitated the development of targeted interventions. By understanding the specific microbial species that are associated with certain diseases or conditions, researchers can develop therapies that specifically target those microbes. This personalized approach has the potential to be more effective and have fewer side effects compared to traditional broad-spectrum antibiotics. In addition to advancements in sequencing technology, other technological innovations have also contributed to the development of microbiome therapeutics. Furthermore, there has been progress in the development of synthetic biology tools that allow for the engineering of microbial communities with desired functions. This opens up new possibilities for designing microbiome-based therapies that can be tailored to individual patients.
On the contrary, high cost of development and production hampers the growth of Europe microbiome therapeutics market.
Based on type, the Europe microbiome therapeutics market is bifurcated into therapeutics and procedure. The procedure segment held 93.3% share of the Europe microbiome therapeutics market in 2022, amassing US$ 91.16 million. It is projected to garner US$ 178.10 million by 2030 to expand at 8.7% CAGR during 2022-2030. The therapeutics segment is further subsegmented into fecal microbiota transplantation (FMT), prebiotics & probiotics, and others.
By application, the Europe microbiome therapeutics market is segmented into metabolic disorder and obesity, C. difficile infection, inflammatory bowel disease, and others. The C. difficile infection segment held 92.1% share of the Europe microbiome therapeutics market in 2022, amassing US$ 90.03 million. It is projected to garner US$ 197.15 million by 2030 to expand at 10.3% CAGR during 2022-2030.
By end user, the Europe microbiome therapeutics market is hospitals and clinics, ambulatory surgical centers, homecare, and others. The hospitals and clinics segment held 55.0% share of the Europe microbiome therapeutics market in 2022, amassing US 53.76 million. It is projected to garner US$ 120.44 million by 2030 to expand at 10.6% CAGR during 2022-2030.
Based on country, the Europe microbiome therapeutics market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany held 25.4% share of Europe microbiome therapeutics market in 2022, amassing US$ 24.83 million. It is projected to garner US$ 54.63 million by 2030 to expand at 10.4% CAGR during 2022-2030.
Key players operating in the Europe microbiome therapeutics market are Caelus Health BV, Enterome SA, Ferring Holdings SA, Vedanta Biosciences Inc, and YSOPIA Bioscience SA, among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com